The Addition of CD20 Monoclonal Antibodies to Lenalidomide Improves Response Rates and Survival in Relapsed/refractory patients with CLL Relative to Lenalidomide Monotherapy – The MD Anderson Cancer Center Experience

Lignende værker

• Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
  af: Strati, Paolo, et al.
  Udgivet: (2019)
• FCR and Bevacizumab (FCR-B) Treatment in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
  af: Jain, Preetesh, et al.
  Udgivet: (2014)
• Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens
  af: Thompson, Philip A., et al.
  Udgivet: (2015)
• Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia
  af: Strati, Paolo, et al.
  Udgivet: (2017)
• Long-term Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) who Discontinue Ibrutinib
  af: Jain, Preetesh, et al.
  Udgivet: (2017)